Literature DB >> 30562119

Genomic Comparison With Supercentenarians Identifies RNF213 as a Risk Gene for Pulmonary Arterial Hypertension.

Hisato Suzuki1, Masaharu Kataoka2, Takahiro Hiraide2, Yuki Aimi3, Yoshitake Yamada4, Yoshinori Katsumata2, Tomohiro Chiba5, Kohsuke Kanekura6, Sarasa Isobe2, Yasunori Sato7, Toru Satoh3, Shinobu Gamou2, Keiichi Fukuda2, Kenjiro Kosaki1.   

Abstract

Entities:  

Keywords:  Bone Morphogenetic Protein Receptors; Hypertension; Pulmonary Artery Whole Exome Sequencing; Pulmonary Moyamoya Disease RING Finger Domains Stenosis; Type II Genetic Association Studies

Mesh：

Substances：

Year:  2018        PMID： 30562119     DOI： 10.1161/CIRCGEN.118.002317

Source DB:  PubMed          Journal:  Circ Genom Precis Med        ISSN： 2574-8300


× No keyword cloud information.
  4 in total

1.  Comprehensive investigation of RNF213 nonsynonymous variants associated with intracranial artery stenosis.

Authors:  Hiroki Hongo; Satoru Miyawaki; Hideaki Imai; Masahiro Shimizu; Shinichi Yagi; Jun Mitsui; Hiroyuki Ishiura; Jun Yoshimura; Koichiro Doi; Wei Qu; Yu Teranishi; Atsushi Okano; Hideaki Ono; Hirofumi Nakatomi; Tsuneo Shimizu; Shinichi Morishita; Shoji Tsuji; Nobuhito Saito
Journal:  Sci Rep       Date:  2020-07-20       Impact factor: 4.379

Review 2.  Ring Finger Protein 213 in Moyamoya Disease With Pulmonary Arterial Hypertension: A Mini-Review.

Authors:  Yuting Luo; Zhixin Cao; Shaoqing Wu; Xunsha Sun
Journal:  Front Neurol       Date:  2022-03-24       Impact factor: 4.003

3.  RNF213-Associated Vascular Disease: A Concept Unifying Various Vasculopathies.

Authors:  Takahiro Hiraide; Hisato Suzuki; Mizuki Momoi; Yoshiki Shinya; Keiichi Fukuda; Kenjiro Kosaki; Masaharu Kataoka
Journal:  Life (Basel)       Date:  2022-04-08

4.  Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension.

Authors:  Mizuki Momoi; Takahiro Hiraide; Yoshiki Shinya; Hiromi Momota; Shogo Fukui; Michiyuki Kawakami; Yuji Itabashi; Keiichi Fukuda; Masaharu Kataoka
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.